The Management of Ocular Surface Squamous Neoplasia (OSSN).
Yeoh CHY, Lee JJR, Lim BXH, Sundar G, Mehta JS, Chan ASY, Lim DKA, Watson SL, Honavar SG, Manotosh R, Lim CHL.
Int J Mol Sci. 2022 Dec 31;24(1):713. doi: 10.3390/ijms24010713.
Ocular surface squamous neoplasia: management and outcomes.
Hӧllhumer R, Williams S, Michelow P.
Eye (Lond). 2021 Jun;35(6):1562-1573. doi: 10.1038/s41433-021-01422-3. Epub 2021 Feb 9.
Tumors of the conjunctiva and cornea.
Shields CL, Shields JA.
Indian J Ophthalmol. 2019 Dec;67(12):1930-1948. doi: 10.4103/ijo.IJO_2040_19.
Medical treatment for ocular surface squamous neoplasia.
Monroy D, Serrano A, Galor A, Karp CL.
Eye (Lond). 2023 Apr;37(5):885-893. doi: 10.1038/s41433-023-02434-x. Epub 2023 Feb 8.
Pathophysiology of ocular surface squamous neoplasia.
Gichuhi S, Ohnuma S, Sagoo MS, Burton MJ.
Exp Eye Res. 2014 Dec;129:172-82. doi: 10.1016/j.exer.2014.10.015. Epub 2014 Oct 18.
Tumors of the ocular surface: A review.
Honavar SG, Manjandavida FP.
Indian J Ophthalmol. 2015 Mar;63(3):187-203. doi: 10.4103/0301-4738.156912.
Ocular surface complications of local anticancer drugs for treatment of ocular tumors.
Moon J, Choi SH, Lee MJ, Jo DH, Park UC, Yoon SO, Woo SJ, Oh JY.
Ocul Surf. 2021 Jan;19:16-30. doi: 10.1016/j.jtos.2020.11.006. Epub 2020 Nov 22.
The role of imaging technologies for ocular surface tumors.
Venkateswaran N, Sripawadkul W, Karp CL.
Curr Opin Ophthalmol. 2021 Jul 1;32(4):369-378. doi: 10.1097/ICU.0000000000000771.
Spontaneous regression of ocular surface squamous neoplasia: Possible etiologic mechanisms in cancer resolution.
Theotoka D, Morkin MI, Naranjo A, Dubovy SR, Karp CL.
Ocul Surf. 2020 Jul;18(3):351-353. doi: 10.1016/j.jtos.2020.03.001. Epub 2020 Mar 10.
Adverse events of antibody-drug conjugates on the ocular surface in cancer therapy.
Domínguez-Llamas S, Caro-Magdaleno M, Mataix-Albert B, Avilés-Prieto J, Romero-Barranca I, Rodríguez-de-la-Rúa E.
Clin Transl Oncol. 2023 Nov;25(11):3086-3100. doi: 10.1007/s12094-023-03261-y. Epub 2023 Jul 15.
